KOL Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma
About The Event
The webinar will feature presentations from Key Opinion Leaders (KOLs) Ernest E. Moore, MD (Denver Health) and Gregory A. Magee, MD (Keck Medicine – USC) who will discuss the current treatment landscape and unmet medical need in the vascular trauma field.
Humacyte’s Human Acellular Vessels™ (HAV™) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV eliminates the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence suggests that it is non-immunogenic and infection-resistant and can become durable living tissue. The webinar will include discussion of recent data on HAV as a potential treatment approach in the repair of vascular trauma injuries.
A question and answer session will follow the formal presentations.